These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7989403)

  • 21. Three Michaelis-Menten pharmacokinetic dosing methods compared with physician dosing of phenytoin in an outpatient neurology practice.
    Spruill WJ; Wade WE; Cobb HH; Akbari S
    Pharmacotherapy; 2001 Nov; 21(11):1407-14. PubMed ID: 11714214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
    Tanaka J; Kasai H; Shimizu K; Shimasaki S; Kumagai Y
    Eur J Clin Pharmacol; 2013 Mar; 69(3):489-97. PubMed ID: 22918614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-point phenytoin dosage predictions in Singapore Chinese.
    Chan E
    J Clin Pharm Ther; 1997 Feb; 22(1):47-52. PubMed ID: 9292403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of enzyme or binding constants using generalized linear models, with particular reference to Michaelis-Menten models.
    van Belle G; Leurgans S; Friel P; Guo SW; Yerby M
    J Pharm Sci; 1989 May; 78(5):413-6. PubMed ID: 2746480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose adjustment of phenytoin for comedication in Japanese patients with epilepsy.
    Fukuoka N; Uno J; Tsukamoto T; Houchi H; Kimura M; Morita S
    Ther Drug Monit; 2009 Feb; 31(1):57-62. PubMed ID: 19077928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.
    Taguchi M; Hongou K; Yagi S; Miyawaki T; Takizawa M; Aiba T; Hashimoto Y
    Drug Metab Pharmacokinet; 2005 Apr; 20(2):107-12. PubMed ID: 15855721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenytoin Michaelis-Menten pharmacokinetics in Saudi patients.
    el-Sayed YM; Islam SI
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):173-8. PubMed ID: 2714918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Population kinetic program for Michaelis-Menten elimination].
    Lü M; Zhou HW; Song JF
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):85-8. PubMed ID: 2403022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Dosing Regimen of Phenytoin for Korean Epilepsy Patients: From Premature Babies to the Elderly.
    Guk J; Lee SG; Chae D; Kim JH; Park K
    J Pharm Sci; 2019 Aug; 108(8):2765-2773. PubMed ID: 30940470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenytoin and IgA concentrations in plasma and saliva in epileptic children.
    Modéer T; Tomson G; Falk O; Rane A
    Acta Paediatr Scand; 1981; 70(3):373-8. PubMed ID: 7246128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of phenytoin in Singapore Chinese.
    Chan E; Ti TY; Lee HS
    Eur J Clin Pharmacol; 1990; 39(2):177-81. PubMed ID: 2253670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Steady-state serum levels of anticonvulsant drugs in Chinese epileptic patients living in Taiwan.
    Lai ML
    Ther Drug Monit; 1985; 7(1):83-6. PubMed ID: 3992625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenytoin dosage adjustment in Saudi epileptics: utilization of steady-state pharmacokinetic parameters.
    Abduljabbar M; Al-Khamis K; Ogunniyi A; Daif AK; Al-Yamani M
    Eur J Neurol; 1999 May; 6(3):331-4. PubMed ID: 10210914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.
    Popović J
    Eur J Drug Metab Pharmacokinet; 2004; 29(3):205-14. PubMed ID: 15537173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1997 Aug; 20(4):346-51. PubMed ID: 9260732
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Drug Monitoring of Phenytoin by Simple, Rapid, Accurate, Highly Sensitive and Novel Method and Its Clinical Applications.
    Shaikh AS; Guo R
    Curr Pharm Biotechnol; 2017; 18(13):1098-1105. PubMed ID: 29437004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human brain phenytoin: correlation with unbound and total serum concentrations.
    Friel PN; Ojemann GA; Rapport RL; Levy RH; Van Belle G
    Epilepsy Res; 1989; 3(1):82-5. PubMed ID: 2917548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug.
    Lee FX; Kong ST; Chan DW; Chan E; Tan WW; Ho PC
    Ther Drug Monit; 2013 Feb; 35(1):54-62. PubMed ID: 23222687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
    Hoppel C; Garle M; Rane A; Sjöqvist F
    Clin Pharmacol Ther; 1977 Mar; 21(3):294-300. PubMed ID: 837648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.